Montanova Capital LLC Sells 9,780 Shares of Danaher Corporation $DHR

Montanova Capital LLC lowered its stake in Danaher Corporation (NYSE:DHR) by 26.9% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,600 shares of the conglomerate’s stock after selling 9,780 shares during the period. Montanova Capital LLC’s holdings in Danaher were worth $5,067,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Camelot Portfolios LLC bought a new stake in Danaher in the second quarter worth $492,000. Headlands Technologies LLC grew its stake in shares of Danaher by 90.5% in the second quarter. Headlands Technologies LLC now owns 2,440 shares of the conglomerate’s stock worth $465,000 after acquiring an additional 1,159 shares during the last quarter. Moore Capital Management LP bought a new position in shares of Danaher during the second quarter valued at $3,224,000. Two Sigma Securities LLC purchased a new position in shares of Danaher in the 2nd quarter worth about $778,000. Finally, Benjamin Edwards Inc. boosted its stake in Danaher by 43.2% in the 2nd quarter. Benjamin Edwards Inc. now owns 19,960 shares of the conglomerate’s stock worth $3,802,000 after purchasing an additional 6,026 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on DHR. Wells Fargo & Company reduced their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. TD Cowen dropped their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Citigroup assumed coverage on shares of Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price target for the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Finally, Evercore reaffirmed an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $228.91.

Danaher Price Performance

Shares of DHR opened at $213.90 on Tuesday. The firm has a fifty day simple moving average of $200.18 and a two-hundred day simple moving average of $192.31. The firm has a market cap of $150.37 billion, a PE ratio of 37.99, a P/E/G ratio of 2.69 and a beta of 0.78. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same period last year, the business posted $0.77 EPS. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, equities analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.